A Study of Participants with Β-Thalassemia Treated with Betibeglogene Autotemcel
Recruiting · NCT06271512
Conditions: Beta-Thalassemia
At a glance
- Research payments reported, 2025
- $252,062
- U.S. investigators named
- 5
- Sites paid
- 5
- Planned or actual enrollment
- 150
About the trial
- Sponsor
- Genetix Biotherapeutics Inc. (with Center for International Blood and Marrow Transplant Research)
- Tested
- No Intervention (other)
- Dates
- Started 2024-01-23; completion 2043-12
- Results posted
- Not yet
The main aim of this study is to collect real-world longitudinal data on participants with β-thalassemia treated with betibeglogene autotemcel (beti-cel) in the post marketing setting. To assess the long-term safety, including the risk of newly diagnosed malignancies, after treatment with beti-cel and evaluate the long-term effectiveness of treatment with beti-cel.
From ClinicalTrials.gov, last updated 2025-02-11. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Genetix Biotherapeutics Inc reported $252,062 in research payments for this study in 2025 (33 payments).
Products named: Zynteglo
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Himal Thakar, MD Hospitalist · Waterbury, CT
- Roy L. Kao, M.D. Hematology & Oncology · Minneapolis, MN
- Banu Aygun, MD Pediatric Hematology & Oncology · New Hyde Park, NY
- Timothy Olson, M.D., PH.D. Pediatric Hematology & Oncology · Philadelphia, PA
- Khaled Yassine, MD Pediatric Hematology & Oncology · Houston, TX
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Biomedical Research Alliance of New York LLC $129,273
- Children's Hospital of Philadelphia, PA $51,545
- Regents of the University of Minnesota $35,390
- Cincinnati Children's Hospital Medical Center, OH $21,050
- Baylor College of Medicine $14,805
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.